Insider transaction
Trupanion Inc. (NASDAQ:TRUP) reported that Chief Operating Officer John R. Gallagher sold 430 shares of common stock on March 30, 2026. The shares changed hands at $25.47 each, producing a total transaction value of $10,952. After this sale, Gallagher directly holds 31,957 shares of the company’s stock.
Context for the trade
The disposition was carried out under a pre-arranged Rule 10b5-1 trading plan that Gallagher adopted on August 20, 2025. The trade occurs while Trupanion’s share price sits close to its 52-week low of $24.32 and after a six-month decline of 41% in the stock price. The company is maintaining a market capitalization of $1.11 billion.
Recent financial performance
Trupanion released its fourth-quarter results for 2025, which were mixed. The company posted earnings per share of $0.13, below the consensus forecast of $0.16. Revenue, however, came in at $376.9 million, exceeding the projected $375.21 million and representing a 12% increase versus the prior year.
Analyst response and valuation commentary
In response to the results and the company’s competitive environment, Stifel lowered its price target on Trupanion to $31 from $35 and maintained a Hold rating. The firm cited concerns about Trupanion’s ability to achieve adequate scale as competition in the pet insurance sector intensifies. Separately, InvestingPro analysis referenced in company commentary suggests the pet insurer may be undervalued at current market levels.
Corporate initiatives
Trupanion also announced a partnership with the Human Animal Bond Research Institute to support research into the human-animal bond. The collaboration will include studies on topics such as the benefits of service dogs for veterans suffering from post-traumatic stress disorder, reflecting the company’s efforts to extend its reach beyond core underwriting and product distribution.
Takeaway
The insider sale by the COO was executed under a pre-arranged plan and involved a modest number of shares. The company’s most recent quarter combined a revenue beat with an EPS miss, and an analyst reaction that trimmed the price target signals investor focus on Trupanion’s growth trajectory and competitive positioning. The announced research collaboration is a strategic move to support broader engagement in areas related to pet health and the human-animal relationship.